Highest-materiality recent filing
Petros Pharmaceuticals CFO Arnold departs; Robert Weinstein appointed as CAO/PFO
Mitchell Arnold mutually separated as VP Finance, Principal Financial & Accounting Officer, effective June 18, 2026.
Petros Pharmaceuticals grants 7M restricted shares to Chairman, two directors, and President
Aggregate 7,000,000 restricted shares granted to Joshua Silverman (Chairman), Bruce Bernstein, Fady Boctor, and Wayne Walker.
Petros Pharmaceuticals grants 7.25M RSUs to executives and directors; 50% vested immediately
Joshua Silverman (Chairman) receives 4,375,000 RSUs; Bruce Bernstein 1,875,000; Fady Boctor 500,000; Wayne Walker 500,000.
Nasdaq notifies Petros Pharmaceuticals of common stock delisting effective Nov 7, 2025
Nasdaq notified Petros on Nov 3, 2025, of intention to delist common stock on Nov 7, 2025.
Petros Pharmaceuticals dismisses CBIZ CPAs, appoints HTL International as auditor
Audit Committee approved dismissal of CBIZ CPAs as auditor effective Aug 29, 2025.
Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust
Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.
Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets
Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.
Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).
Nasdaq notified Petros on Apr 8 it fails $2.5M minimum stockholders' equity requirement, adding to existing bid price deficiency.
Company terminated Marcum LLP as auditor on April 5, 2025, and engaged CBIZ CPAs P.C. as new independent auditor for FY 2025.
Petros Pharmaceuticals Prices $9.6 Million Public Offering of Common Stock and Warrants
Petros Pharmaceuticals entered securities purchase agreement for 13,950,012 units and 26,049,988 pre-funded units at $0.24 and $0.2399 per unit.
Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.
Metuchen failed to pay installment due Oct 1, 2024; all obligations accelerated.
Petros Pharma stockholders OK reverse stock split up to 1:25
Directors Silverman, Bernstein, Walker elected to one-year terms.
Petros Pharma reduces President Boctor's base salary to $280K, sets Dec 31 termination
Base salary cut from $350K to $280K effective Oct 16, 2024.
Petros Pharmaceuticals amends Series A Preferred to grant voting rights at $2.25 conversion price
Amendment grants Series A Preferred holders voting rights on as-converted basis at $2.25/share conversion price.
Two directors resign from Petros Pharmaceuticals board without disagreement
John Shulman resigned as director effective Oct 1, 2024; no disagreement cited.
Petros Pharmaceuticals sets 2024 annual meeting for Nov 20; shareholder proposals due Sept 29
Annual meeting scheduled for November 20, 2024; record date October 14, 2024.
Petros enters waiver/amendment with investors covering Dec 2023 equity awards and warrant terms
Waives breach from Dec 21, 2023 issuance of 348,711 shares/options; deems them Excluded Securities.
Petros Pharmaceuticals dismisses EisnerAmper as auditor, appoints Marcum; cites material weaknesses
Audit committee dismissed EisnerAmper as independent auditor on January 8, 2024; engaged Marcum effective immediately.
Elected directors John Shulman, Joshua Silverman, Bruce Bernstein, Gregory Bradley, Wayne Walker with over 88% of votes cast for each.
Petros Pharmaceuticals awards 49,645 shares and options to President Boctor, options to VP Arnold
One-time grant to President & CCO Fady Boctor: 49,645 common shares and options for 109,066 shares at $1.41.
Petros Pharmaceuticals amends Series A Preferred Stock redemption and conversion procedures
Filed Certificate of Amendment to Series A Convertible Preferred Stock with Delaware Secretary of State on Sept 29, 2023.
Petros shareholders approved authorized share increase to 250M and incentive plan share increase
Authorized common shares increased from 150M to 250M via charter amendment filed Sept 14, 2023.
Petros Pharmaceuticals lowers stockholder quorum requirement from majority to one-third
Board approved amendment reducing quorum from majority to one-third of outstanding voting shares.
Petros Pharmaceuticals raises $15M via private placement to advance OTC STENDRA
Issued 15,000 Series A Convertible Preferred shares (stated value $1,000 each) and warrants for up to 6,666,668 common shares at $2.25.
Petros Pharmaceuticals effectuates 1-for-10 reverse stock split effective Nov 30, 2022
Stockholders approved reverse split at ratio of 1-for-10 at Nov 29 annual meeting.
Petros Pharma Q3 net sales negative $1.4M, net loss $13.8M on excessive returns
Net sales of -$1.4M vs $2.1M YoY; Prescription Medicines segment net sales -$2.1M due to expired product returns.
Petros Pharmaceuticals reports Q2 net sales of $4.2M, first positive adjusted EBITDA of $0.2M
Q2 net sales of $4.2M, up 68% from $2.5M in Q2 2021; net loss narrowed to $1.8M from $2.1M.
Petros Pharmaceuticals denies fraudulent acquisition press release; reports to Nasdaq
A press release issued July 28, 2022 claiming an acquisition of Petros was fraudulent and not authorized by the company.
Petros Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq letter on June 22, 2022 for bid price <$1.00 over 30 consecutive business days ended June 21, 2022.
Signed Sponsored Research Agreement and Option Agreement with Wellman Center of Massachusetts General Hospital.
Petros Pharma reports 2021 net sales $7.8M, net loss down 56% to $9.0M
Net sales $7.8M vs $9.6M in 2020; prescription sales fell to $4.6M due to competitive coupons.
Petros Pharmaceuticals board sets annual say-on-pay votes after advisory vote
Board determined future Say-on-Pay Votes will be held every year, consistent with stockholder preference expressed at 2021 Annual Meeting.
Subsidiary President Andrew Gesek resigns; Petros to integrate his role
Andrew Gesek resigned as President of Timm Medical Technologies effective Feb 28, 2022; no disagreement cited.
Petros Pharmaceuticals signs manufacturing agreement with Thermo Fisher's Patheon for Stendra
Metuchen (Petros subsidiary) and Patheon (Thermo Fisher) will collaborate on tech transfer and validation to manufacture Stendra at Patheon's Cincinnati facility.
Petros subsidiary settles VIVUS disputes, issues $10.2M promissory note at 6% through 2027
Metuchen settles with VIVUS, forgives $9.6M in liabilities and retains ~$7.3M of API inventory.
Petros Pharmaceuticals raises $7.5M in registered direct offering and private placement
Sold 2,186,589 shares at $3.43 each to accredited investors, including largest shareholder.
All five director nominees (Shulman, Silverman, Bernstein, Bradley, Walker) re-elected with >99% votes cast in favor.
Petros Pharmaceuticals raises $10M in registered direct offering and private placement
Gross proceeds of $10M from sale of 3,333,333 shares at $3.00/share; net proceeds ~$9.3M.
Petros Pharmaceuticals sets Dec 22, 2021 annual meeting; Nov 27 deadline for shareholder proposals
Annual Meeting set for December 22, 2021; record date November 18, 2021.
Petros Pharma Q3 net sales fall 37% to $2.2M; net loss narrows to $1.7M
Net sales $2.2M, down from $3.5M YoY; Prescription Medicines net sales declined 47% due to higher allowances and returns.
Petros Pharmaceuticals raises ~$5.7M in registered direct offering led by largest shareholder
Offering of 3,323,616 shares at $1.715 per share; warrants for same number at same price, 5-year term.
On June 18, 2026, the board of directors (the “Board”) of the Company appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately.
On June 18, 2026, Petros Pharmaceuticals, Inc. (the “Company”) and Mitchell Arnold, who served as the Company’s Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, mutually agreed to the separation of Mr. Arnold from such roles, effective as of June 18, 2026
On October 1, 2024, John Shulman, who served as a member of the board of directors (the “Board”) of Petros Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as director of the Company, effective as of October 1, 2024.
On October 2, 2024, Greg Bradley, who served as a member of the Board tendered his resignation from his role as director of the Company, effective as of October 2, 2024.
On February 28, 2022 (the “Termination Date”), Andrew Gesek resigned from his position as President of Timm Medical Technologies, Inc., a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. (the “Company”), effective immediately.
Max materiality 0.90 · Median 0.60 · Most common event other_material